Acylation of Exenatide by Glycolic Acid and its Anti-Diabetic Activities in db/db Mice
详细信息 查看全文
- 作者：Rongcai Liang (1) (2) (3)
Xiang Li (2) (3)
Renyu Zhang (2) (3)
Yanan Shi (4)
Aiping Wang (1) (3)
Daquan Chen (1)
Kaoxiang Sun (1) (3)
Wanhui Liu (1) (3)
Youxin Li (2) (3) - 关键词：acylation ; anti ; diabetic activity ; exenatide ; glycolic acid ; stability
- 刊名：Pharmaceutical Research
- 出版年：2014
- 出版时间：August 2014
- 年：2014
- 卷：31
- 期：8
- 页码：1958-1966
- 全文大小：1,486 KB
- 参考文献：1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047鈥?3. CrossRef
2. Jaime A, Davidson MD. Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. Cleve Clin J Med. 2009;76:S28鈥?8.
3. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5:262鈥?. CrossRef
4. Kulasa KM. The current status of exenatide once weekly. Clin Med Insights Ther. 2011;3:221鈥?2. CrossRef
5. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696鈥?05. CrossRef
6. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, / et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372:1240鈥?0. CrossRef
7. Kwak HH, Shim WS, Hwang S, Son MK, Kim YJ, Kim TH, / et al. Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in zucker diabetic fatty (ZDF) rats. Pharm Res. 2009;26:2504鈥?2. CrossRef
8. Lucke A, Kiermaier J, G枚pferich A. Peptide acylation in poly(ahydroxy esters). Pharm Res. 2002;19:175鈥?1. CrossRef
9. Murty SB, Thanoo BC, Wei Q, DeLuca PP. Impurity formation studies with peptide-loaded polymeric microspheres Part I. In vivo evaluation. Int J Pharm. 2005;297:50鈥?1. CrossRef
10. Lucke A, Kiermaier J, G枚pferich A. Acylation of peptides by lactic acid solutions. Eur J Pharm Biopharm. 2003;55:27鈥?3. CrossRef
11. Ahn JH, Park EJ, Lee HS, Lee KC, Na DH. Reversible blocking of amino groups of octreotide for the inhibition of formation of acylated peptide impurities in poly(lactide-co-glycolide) delivery systems. AAPS PharmSciTech. 2011;12:1220鈥?. CrossRef
12. Houchin ML, Neuenswander SA, Topp EM. Effect of excipients on PLGA film degradation and the stability of an incorporated peptide. J Control Release. 2007;117:413鈥?0. CrossRef
13. Park E, Tak TH, Na DH, Lee KC. Effect of PEGylation on stability of peptide in poly(lactide-co-glycolide) microspheres. Arch Pharm Res. 2010;33:1111鈥?. CrossRef
14. Na DH, DeLuca PP. PEGylation of octreotide: I. Separation of positional isomers and stability against acylation by poly(D, L-lactide-co-glycolide). Pharm Res. 2005;22:736鈥?2. CrossRef
15. Ghassemi AH, van Steenbergen MJ, Barendregt A, Talsma H, Kok RJ, van Nostrum CF, / et al. Controlled release of octreotide and assessment of peptide acylation from poly(D, L-lactide-co-hydroxymethyl glycolide) compared to PLGA microspheres. Pharm Res. 2012;29:110鈥?0. CrossRef
16. Sophocleous AM, Zhang Y, Schwendeman SP. A new class of inhibitors of peptide sorption and acylation in PLGA. J Control Release. 2009;137:179鈥?4. CrossRef
17. Zhang Y, Sophocleous AM, Schwendeman SP. Inhibition of peptide acylation in PLGA microspheres with water-soluble divalent cationic salts. Pharm Res. 2009;26:1986鈥?4. CrossRef
18. Zhang Y, Schwendeman SP. Minimizing acylation of peptides in PLGA microspheres. J Control Release. 2012;162:119鈥?6. CrossRef
19. Na DH, Lee JE, Jang SW, Lee KC. Formation of acylated growth hormone-releasing peptide-6 by poly(lactide-co-glycolide) and its biological activity. AAPS PharmSciTech. 2007;8:E1鈥?. CrossRef
20. Kidwai SA, Ansari AA, Salahuddin A. Effect of succinylation (3-carboxy- propionylation) on the conformation and immunological activity of ovalbumin. Biochem J. 1976;155:171鈥?0.
21. Qasim MA, Salahuddin A. Changes in conformation and immunological activity of ovalbumin during its modification with different acid anhydrides. Biochim Biophys Acta. 1978;536:50鈥?3. CrossRef
22. Murase S, Yumoto N, Petukhov MG, Yoshikawa S. Acylation of the alpha-amino group in neuropeptide Y(12鈥?6) increases binding affinity for the Y2 receptor. J Biochem Tokyo. 1996;119:37鈥?1. CrossRef
23. Schwendeman SP, Costantino HR, Gupta RK, Tobio M, Chang AC, Alonso MJ, / et al. Strategies for stabilising tetanus toxoid towards the development of a single-dose tetanus vaccine. Dev Biol Stand. 1996;87:293鈥?06.
24. Liang RC, Li X, Shi YN, Wang AP, Sun KX, Liu WH, / et al. Effect of water on exenatide acylation in poly(lactide-co-glycolide) microspheres. Int J Pharm. 2013;454:344鈥?3. CrossRef
25. Liang RC, Zhang RY, Li X, Wang AP, Chen DQ, Sun KX, / et al. Stability of Exenatide in poly(D, L-lactide-co-glycolide) solutions: a simplified investigation on the peptide degradation by the polymer. Eur J Pharm Sci. 2013;50:502鈥?0. CrossRef
26. Hudson FM, Andersen NH. Exenatide: NMR/CD evaluation of the medium dependence of conformation and aggregation state. Pept Sci. 2004;76:298鈥?08. CrossRef
27. Doyle BL, Pollo MJ, Pekar AH, Roy ML, Thomas BA, Brader ML. Biophysical signatures of noncovalent aggregates formed by a glucagonlike peptide-1 analog: a prototypical example of biopharmaceutical aggregation. J Pharm Sci. 2005;94:2749鈥?3. CrossRef
28. Riedel MJ, Lee CWK, Kieffer TJ. Engineered glucagon-like peptide-1-producing hepatocytes lower plasma glucose levels in mice. Am J Physiol Endocrinol Metab. 2009;296:E936鈥?4. CrossRef
29. Willard FS, Sloop KW. Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor. Exp Diabetes Res. 2012;2012:12. doi:10.1155/2012/470851 .
30. Chae SY, Choi YG, Son S, Jung SY, Lee DS, Lee KC. The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics. J Control Release. 2010;144:10鈥?. CrossRef
31. Chae SY, Jin CH, Shin JH, Son S, Kim TH, Lee S, / et al. Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs. J Control Release. 2010;142:206鈥?3. CrossRef
32. Hoare SRJ. Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. DDT. 2005;10:417鈥?7. CrossRef
33. L贸pez de Maturana R, Donnelly D. The glucagon-like peptide-1 receptor binding site for the N-terminus of GLP-1 requires polarity at Asp198 rather than negative charge. FEBS Lett. 2002;530:244鈥?. CrossRef
34. Murty SB, Na DH, Thanoo BC, DeLuca PP. Impurity formation studies with peptide-loaded polymeric microspheres Part II. In vitro evaluation. Int J Pharm. 2005;297:62鈥?2. CrossRef
35. Houchin ML, Topp EM. Chemical degradation of peptides and proteins in PLGA: a review of reactions and mechanisms. J Pharm Sci. 2008;97:2395鈥?04. CrossRef
36. Giteau A, Venier-Julienne MC, Aubert-Pouessel A, Benoit JP. How to achieve sustained and complete protein release from PLGA-based microparticles? Int J Pharm. 2008;350:14鈥?6. CrossRef
37. Van de Weert M, Hennink WE, Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res. 2000;17:1159鈥?7. CrossRef - 作者单位：Rongcai Liang (1) (2) (3)
Xiang Li (2) (3)
Renyu Zhang (2) (3)
Yanan Shi (4)
Aiping Wang (1) (3)
Daquan Chen (1)
Kaoxiang Sun (1) (3)
Wanhui Liu (1) (3)
Youxin Li (2) (3)
1. School of Pharmacy, Yantai University, No. 32 Qingquan Road, 264005, Yantai, Shandong Province, China
2. College of Life Science, Jilin University, NO.2699 Qianjin Street, 130012, Changchun, Jilin Province, China
3. State Key Laboratory of Long-Acting and Targeting Drug Delivery System, No. 9 Baoyuan Road, 264003, Yantai, Shandong Province, China
4. School of Pharmacy, Binzhou Medical University, No. 346 Guanhai Road, 264003, Yantai, Shandong Province, China - ISSN：1573-904X
文摘